Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.
Also called NCT05004675
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 166 participants
- Registry
-
NCT05004675
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France, Germany, Norway, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05004675. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-20 (actual); primary completion 2024-05-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients
- Acronym
- LIBerate-VI
- Condition
- Hypercholesterolemia
- Condition
- Atherosclerotic Ischemic Disease
- Intervention (Biological)
- lerodalcibep
- Intervention (Drug)
- Inclisiran
- Lead sponsor
- LIB Therapeutics LLC
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct05004675- Content hash
23bc366c255af64386c51abc71453ca7f6339b6a4135449b3c44e16ed676af41